-
Communities
-
Explore Vanderbilt communities
By latest
Featured community
Creative Data Solutions (CDS) is a Vanderbilt Shared Resource and has extensive experience in providing effective and robust solutions to challenges pertaining to research data using modern informatics and bioinformatics approaches.
-
- Resources
-
People
-
Publications
-
Explore publications
-
Keyword Connections
Connections to Skin Neoplasms are shown below. Double-click or tap a node for more information.
Please note that publication matches are limited to 40 in this view. If you expected more, please view all publication matches for Skin Neoplasms.
Members
- No matching connections
Resources
- No matching connections
Communities
- No matching connections
Publications
- RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, Preece N, Robert L, Otte NJ, Mok S, Kee D, Ma Y, Zhang C, Habets G, Burton EA, Wong B, Nguyen H, Kockx M, Andries L, Lestini B, Nolop KB, Lee RJ, Joe AK, Troy JL, Gonzalez R, Hutson TE, Puzanov I, Chmielowski B, Springer CJ, McArthur GA, Sosman JA, Lo RS, Ribas A, Marais R
(2012) N Engl J Med 366: 207-15 - Improved survival with ipilimumab in patients with metastatic melanoma.
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ
(2010) N Engl J Med 363: 711-23 - Pathological responses to oncogenic Hedgehog signaling in skin are dependent on canonical Wnt/beta3-catenin signaling.
Yang SH, Andl T, Grachtchouk V, Wang A, Liu J, Syu LJ, Ferris J, Wang TS, Glick AB, Millar SE, Dlugosz AA
(2008) Nat Genet 40: 1130-5 - Genomic Classification of Cutaneous Melanoma.
Cancer Genome Atlas Network
(2015) Cell 161: 1681-96 - Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5.
Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V
(1997) Science 277: 225-8 - Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.
Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, Richards J, Michener T, Balogh A, Heller KN, Hodi FS
(2012) Lancet Oncol 13: 459-65 - Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, Fecher LA, Millward M, McArthur GA, Hwu P, Gonzalez R, Ott PA, Long GV, Gardner OS, Ouellet D, Xu Y, DeMarini DJ, Le NT, Patel K, Lewis KD
(2013) J Clin Oncol 31: 482-9 - Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation.
Leisenring W, Friedman DL, Flowers ME, Schwartz JL, Deeg HJ
(2006) J Clin Oncol 24: 1119-26 - Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma.
Johnson DB, Saranga-Perry V, Lavin PJ, Burnette WB, Clark SW, Uskavitch DR, Wallace DE, Dickson MA, Kudchadkar RR, Sosman JA
(2015) J Clin Oncol 33: e122-4 - Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study.
Margolin KA, Liu PY, Flaherty LE, Sosman JA, Walker MJ, Smith JW, Fletcher WS, Weiss GR, Unger JM, Sondak VK
(1998) J Clin Oncol 16: 664-9 - BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.
Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, Weber JS, Nguyen H, Cheverton P, Chen D, Peterson AC, Carson WE, O'Day SJ
(2012) J Clin Oncol 30: 34-41 - Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS
(2014) J Clin Oncol 32: 1020-30 - When will melanoma vaccines be proven effective?
Sosman JA, Weeraratna AT, Sondak VK
(2004) J Clin Oncol 22: 387-9 - Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.
Sosman JA, Unger JM, Liu PY, Flaherty LE, Park MS, Kempf RA, Thompson JA, Terasaki PI, Sondak VK, Southwest Oncology Group
(2002) J Clin Oncol 20: 2067-75 - Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort.
Meadows AT, Friedman DL, Neglia JP, Mertens AC, Donaldson SS, Stovall M, Hammond S, Yasui Y, Inskip PD
(2009) J Clin Oncol 27: 2356-62 - Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Kim KB, Weber JS, Hersey P, Long GV, Lawrence D, Ott PA, Amaravadi RK, Lewis KD, Puzanov I, Lo RS, Koehler A, Kockx M, Spleiss O, Schell-Steven A, Gilbert HN, Cockey L, Bollag G, Lee RJ, Joe AK, Sosman JA, Ribas A
(2013) J Clin Oncol 31: 1767-74 - Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma.
Han D, Zager JS, Shyr Y, Chen H, Berry LD, Iyengar S, Djulbegovic M, Weber JL, Marzban SS, Sondak VK, Messina JL, Vetto JT, White RL, Pockaj B, Mozzillo N, Charney KJ, Avisar E, Krouse R, Kashani-Sabet M, Leong SP
(2013) J Clin Oncol 31: 4387-93 - Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma.
McArthur GA, Puzanov I, Amaravadi R, Ribas A, Chapman P, Kim KB, Sosman JA, Lee RJ, Nolop K, Flaherty KT, Callahan J, Hicks RJ
(2012) J Clin Oncol 30: 1628-34 - The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.
Kaufman HL, Kirkwood JM, Hodi FS, Agarwala S, Amatruda T, Bines SD, Clark JI, Curti B, Ernstoff MS, Gajewski T, Gonzalez R, Hyde LJ, Lawson D, Lotze M, Lutzky J, Margolin K, McDermott DF, Morton D, Pavlick A, Richards JM, Sharfman W, Sondak VK, Sosman J, Steel S, Tarhini A, Thompson JA, Titze J, Urba W, White R, Atkins MB
(2013) Nat Rev Clin Oncol 10: 588-98 - High definition profiling of mammalian DNA methylation by array capture and single molecule bisulfite sequencing.
Hodges E, Smith AD, Kendall J, Xuan Z, Ravi K, Rooks M, Zhang MQ, Ye K, Bhattacharjee A, Brizuela L, McCombie WR, Wigler M, Hannon GJ, Hicks JB
(2009) Genome Res 19: 1593-605 - Sunlight and reduced risk of cancer: is the real story vitamin D?
Egan KM, Sosman JA, Blot WJ
(2005) J Natl Cancer Inst 97: 161-3 - Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment.
Vilgelm AE, Johnson CA, Prasad N, Yang J, Chen SC, Ayers GD, Pawlikowski JS, Raman D, Sosman JA, Kelley M, Ecsedy JA, Shyr Y, Levy SE, Richmond A
(2016) J Natl Cancer Inst 108: djv406 - Epithelial stem cell mutations that promote squamous cell carcinoma metastasis.
White RA, Neiman JM, Reddi A, Han G, Birlea S, Mitra D, Dionne L, Fernandez P, Murao K, Bian L, Keysar SB, Goldstein NB, Song N, Bornstein S, Han Z, Lu X, Wisell J, Li F, Song J, Lu SL, Jimeno A, Roop DR, Wang XJ
(2013) J Clin Invest 123: 4390-404 - Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.
Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS
(2014) Cancer Discov 4: 80-93 - A splice variant of alpha 6 integrin is associated with malignant conversion in mouse skin tumorigenesis.
Tennenbaum T, Belanger AJ, Glick AB, Tamura R, Quaranta V, Yuspa SH
(1995) Proc Natl Acad Sci U S A 92: 7041-5 - Loss of p120 catenin and links to mitotic alterations, inflammation, and skin cancer.
Perez-Moreno M, Song W, Pasolli HA, Williams SE, Fuchs E
(2008) Proc Natl Acad Sci U S A 105: 15399-404 - Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma.
Wang NJ, Sanborn Z, Arnett KL, Bayston LJ, Liao W, Proby CM, Leigh IM, Collisson EA, Gordon PB, Jakkula L, Pennypacker S, Zou Y, Sharma M, North JP, Vemula SS, Mauro TM, Neuhaus IM, Leboit PE, Hur JS, Park K, Huh N, Kwok PY, Arron ST, Massion PP, Bale AE, Haussler D, Cleaver JE, Gray JW, Spellman PT, South AP, Aster JC, Blacklow SC, Cho RJ
(2011) Proc Natl Acad Sci U S A 108: 17761-6 - Collision of chronic lymphocytic leukemia/small lymphocytic lymphoma and melanoma.
Dueber JC, Coffin CM
(2013) Blood 121: 4819 - Intraocular involvement of mycosis fungoides associated with immunophenotypic switch from CD4 to CD8.
Braue JA, Daniels AB, Zwerner JP, Kim SJ, Zic JA
(2018) Blood 131: 932-935 - Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides.
McGirt LY, Jia P, Baerenwald DA, Duszynski RJ, Dahlman KB, Zic JA, Zwerner JP, Hucks D, Dave U, Zhao Z, Eischen CM
(2015) Blood 126: 508-19 - Mice lacking the p53/p63 target gene Perp are resistant to papilloma development.
Marques MR, Horner JS, Ihrie RA, Bronson RT, Attardi LD
(2005) Cancer Res 65: 6551-6 - Induction of melanoma in murine macrophage inflammatory protein 2 transgenic mice heterozygous for inhibitor of kinase/alternate reading frame.
Yang J, Luan J, Yu Y, Li C, DePinho RA, Chin L, Richmond A
(2001) Cancer Res 61: 8150-7 - Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma.
Seftor RE, Seftor EA, Koshikawa N, Meltzer PS, Gardner LM, Bilban M, Stetler-Stevenson WG, Quaranta V, Hendrix MJ
(2001) Cancer Res 61: 6322-7 - p38delta Mitogen-activated protein kinase is essential for skin tumor development in mice.
Schindler EM, Hindes A, Gribben EL, Burns CJ, Yin Y, Lin MH, Owen RJ, Longmore GD, Kissling GE, Arthur JS, Efimova T
(2009) Cancer Res 69: 4648-55 - Modulation of oxidant formation in mouse skin in vivo by tumor-promoting phorbol esters.
Marnett LJ, Ji C
(1994) Cancer Res 54: 1886s-1889s - Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer.
Margolin K, Atkins MB, Dutcher JP, Ernstoff MS, Smith JW, Clark JI, Baar J, Sosman J, Weber J, Lathia C, Brunetti J, Cihon F, Schwartz B
(2007) Clin Cancer Res 13: 3312-9 - Molecular targets in melanoma from angiogenesis to apoptosis.
Sosman JA, Puzanov I
(2006) Clin Cancer Res 12: 2376s-2383s - BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.
Hutchinson KE, Lipson D, Stephens PJ, Otto G, Lehmann BD, Lyle PL, Vnencak-Jones CL, Ross JS, Pietenpol JA, Sosman JA, Puzanov I, Miller VA, Pao W
(2013) Clin Cancer Res 19: 6696-702 - A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.
Su Y, Amiri KI, Horton LW, Yu Y, Ayers GD, Koehler E, Kelley MC, Puzanov I, Richmond A, Sosman JA
(2010) Clin Cancer Res 16: 348-57 - Innovations and challenges in melanoma: summary statement from the first Cambridge conference.
Atkins MB, Elder DE, Essner R, Flaherty KT, Gajewski TF, Haluska FG, Hwu P, Keilholz U, Kirkwood JM, Mier JW, Ross MI, Slingluff CL, Sondak VK, Sosman JA, Weinstock MA, King L
(2006) Clin Cancer Res 12: 2291s-2296s
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.
